NanoLogix Tech Included in Tuberculosis Report
HUBBARD, Ohio -- NanoLogix Inc. announced that its sandwiched-membrane BNP rapid testing technology for tuberculosis is cited in the World Health Organization’s report, 2014 Tuberculosis Diagnostics Technology and Market Landscape.
This is the second year that NanoLogix was mentioned in the annual report, published by UNITAID, based in Geneva, Switzerland. The report highlights current and emerging technologies from more than 80 manufacturers and developers.
NanoLogix anticipates having its BNP technology included in TB studies in Africa and Australia in 2015. The BNP technology is patent pending in the United States, China, India and Brazil and received patents in Japan and Russia in 2014 and also notice of allowance of patent in the European Union in 2014, with the EU patent issuance expected in October 2014.
The company also announced it has received a purchase order from The Ohio State University for provision of laboratory supplies to at least two departments on the Columbus campus, making its first delivery Sept. 25. Other institutions ordering NanoLogix products include University of Colorado-Boulder, Massachusetts Institute of Technology, Worcester Polytechnic Institute and Cardiff University.
Other customers include Abbott Labs, personal care companies, food processing companies, soil-testing companies, the U.S. Environmental Protection Agency and others who currently cannot be named due to contractual agreements.
Pictured: NanoLogix CEO Bret Barnhizer.
Published by The Business Journal, Youngstown, Ohio.
CLICK HERE to subscribe to our twice-monthly print edition and to our free daily email headlines.